Establishing Acceptable Limits of Residual DNA

References

1. 1.↵
   1. Lewis A. M. Jr..,
   2. Krause P.,
   3. Peden K.

   A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture. Dev. Biol. (Basel) 2001, 106, 513–35.

   OpenUrlPubMed
2. 2.↵
   1. Petricciani J. C.,
   2. Regan P. J.

   Risk of neoplastic transformation from cellular DNA: calculations using the oncogene model. Dev. Biol. Stand. 1987, 68, 43–49.

   OpenUrlPubMed
3. 3.↵
   1. Petricianni J. C.,
   2. Horaud F. N.

   DNA, dragons and sanity: residual cellular DNA in biotechnological products. Biologicals 1995, 23 (3), 233–238.

   OpenUrlPubMed
4. 4.↵
   1. Petricciani J.,
   2. Loewer J.

   An overview of cell DNA issues. Dev. Biol. (Basel) 2001, 106, 275–782, discussion 317–329.

   OpenUrlPubMed
5. 5.↵
   1. Sheng L.,
   2. Cai F.,
   3. Zhu Y.,
   4. Pal A.,
   5. Athanasiou M.,
   6. Orrison B.,
   7. Blair D. G.,
   8. Hughes S. H.,
   9. Coffin J. M.,
   10. Lewis A. M.,
   11. Peden K.

   Oncogenicity of DNA in vivo: tumor induction with expression plasmids for activated H-ras and c-myc. Biologicals 2008, 36 (3), 184–197.

   OpenUrlPubMed
6. 6.↵
   1. Peden K.,
   2. Sheng L.,
   3. Pal A.,
   4. Lewis A.

   Biological activity of residual cell substrate DNA. Dev. Biol. (Basel) 2006, 123, 45–56, discussion 55–73.

   OpenUrlPubMed
7. 7.↵
   1. Hopps H. E.,
   2. Petricciani J. C.

   In Vitro Cellular and Development Biology. Monograph No. 6: Abnormal Cells, New Products, and Risks; Hopps H. E., Petricciani J. C., Eds.; Tissue Culture Association: Gaithersburg, MD, 1985.
8. 8.↵
   1. Temin H. M.

   Overview of biological effects of addition of DNA molecules to cells. J. Med. Virol. 1990, 31 (1), 13–17.

   OpenUrlPubMed
9. 9.↵
   WHO (World Health Organization) Meeting Report Study group on cell substrates for production of biologicals. June 11 and 12, 2007; 1–30.
10. 10.↵
    FDA Guidance for Industry: Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications. U.S. Department of Health and Human Services, Food and Drug Administration Center for Biologics Evaluation and Research, February, 2010.
11. 11.↵
    U.S. FDA. Pharamaceutical cGMPs for the 21^st Century: A Risk-Based Approach: Final Report, 2004.
12. 12.↵
    ICH Q8: Pharmaceutical Development, 2006.
13. 13.↵
    1. Yang H.,
    2. Zhang L.,
    3. Galinski M.

    A probabilistic model for risk assessment of residual host cell DNA in biological products. Vaccine, 2010, 28 (19), 3308–3311.

    OpenUrlPubMed
14. 14.↵
    1. Krause P. R.,
    2. Lewis A. M. Jr..

    Safety of viral DNA in biological products. Biologicals 2008, 36 (3), 184–197.

    OpenUrlPubMed
15. 15.↵
    1. Boyd S.,
    2. Vandenberghe L.

    Convex Optimization. Cambridge University Press, 2004.
16. 16.↵
    www.fda.ohrms/dockets/ac/05/transcripts/2005-4188t1.pdf.